Browse 642 small cell lung cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.
Filter
1
Filter results
Results: 642
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
for
Small Cell Lung Cancer
Location: Detroit MI, Los Angeles CA
Sponsor: SciTech Development, Inc.
Sex: All
Age: 18+
Code: NCT06922539
Phase1, Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
for
Non-Small Cell Lung Cancer
Location: Boston MA, Mineola NY, New York NY, Philadelphia PA,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT07100080
Phase2, Phase3, Recruiting
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
for
Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma,
Location: Pittsburgh PA
Sponsor: Diwakar Davar
Sex: All
Age: 18+
Code: NCT07223424
Phase2, Recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Location: New York NY, New Brunswick NJ, Morristown NJ,
Sponsor: Pierre Fabre Medicament
Sex: All
Age: 18+
Code: NCT04913285
Phase1, Recruiting
Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer
for
Non Small Cell Lung Cancer, Metastatic Lung Cancer
Location: Montreal
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Sex: All
Age: 18+
Code: NCT06622174
Phase1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer
for
Non-Small Cell Lung Cancer, ICI-refractory
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT07133425
Phase2, Recruiting
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
for
Small Cell Lung Cancer
Location: Orlando FL, Grand Rapids MI, Omaha NE
Sponsor: Amgen
Sex: All
Age: 18 - 70+
Code: NCT07778316
Phase3, Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
for
Non-Small-Cell Lung Cancer,
Location: Lake Success NY, New York NY, Philadelphia PA, Ottawa,
Sponsor: ArriVent BioPharma, Inc.
Sex: All
Age: 18+
Code: NCT07185997
Phase3, Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)